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Abstract 37 
Objective: Fatigue is a major disabling symptom in many chronic diseases including multiple 38 
sclerosis (MS) but treatment options are limited. We developed a fully automated, interactive, 39 
online fatigue management program (ELEVIDA) based on principles of cognitive behavioral 40 
therapy (CBT) and related psychotherapeutic approaches (e.g. mindfulness) and tested its 41 
effectiveness for reducing fatigue in MS.   42 
Methods: Patients with MS and self-reported fatigue were recruited via the website of the 43 
German MS Society and assigned via an automated randomization generator (1:1, no blocking 44 
or stratification) to a 12 week online intervention (ELEVIDA, n=139, 82% female, mean age 45 
40.8, median PDDS 3.0) or a standard-care control group (n=136, 79% female, mean age 46 
41.9, median PDDS 3.0). The primary outcome was the Chalder Fatigue Scale. Outcomes 47 
were assessed at baseline, at week 12 (post intervention), and at follow-up (week 24).  48 
Results: Compared to the control group, significantly greater reductions in Chalder Fatigue 49 
Scale scores were seen in the ELEVIDA group at week 12 (primary endpoint, intention-to-50 
treat analysis: between group mean difference 2·74 points; 95% CI 1·16; 4·32; p=0·0007; 51 
effect size d=0·53), with effects sustained at week 24 (intention-to-treat analysis: between 52 
group mean difference 2·19 points; 95% CI 0·57; 3·82; p=0·0080).  53 
Conclusions: Our trial provides evidence for the effectiveness of a fully automated, internet-54 
based intervention to reduce fatigue in MS. Interventions such as ELEVIDA may be a suitable 55 
low-barrier, cost effective treatment option for MS fatigue.  56 
Trial registration number: The trial was prospectively registered with the ISRCTN registry 57 
(number ISRCTN25692173). 58 
 59 
  60 
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INTRODUCTION 61 
Fatigue is a common and disabling symptom in many neurological disorders such as stroke 1, 62 
traumatic brain injury 2, Parkinson’s disease 3 and others. In patients with multiple sclerosis 63 
(MS), fatigue affects up to 70% of patients 4 and more than three quarters of these describe it 64 
as their most disabling problem 5. Importantly, fatigue is one of the most frequent causes for 65 
MS-related retirement 6 and there is an association with depression 7 and cognitive 66 
impairment 8.  67 
Despite the immediate clinical importance, treatment options for MS-fatigue are limited (for a 68 
systematic review, see 9). Meta-analyses found no conclusive evidence for pharmacological 69 
treatment 10. In contrast, the potential benefit of non-pharmacological interventions has been 70 
supported by several meta-analyses10-13. Cognitive behavioral therapy (CBT)-based 71 
approaches have been shown to be particularly effective in reducing MS-related fatigue (e.g. 72 
14), which has also been confirmed by meta-analyses 10 15.  73 
However, there is a paucity of large RCTs in this area. Moreover, standard behavioral 74 
treatments may not be suitable for all MS patients: For example, mobility impairments may 75 
interfere with patients’ ability to regularly travel to the therapist’s office. In addition, MS-76 
related symptoms such as cognitive dysfunction or fatigue itself may make it difficult for 77 
patients to complete standard length, weekly sessions with a therapist. Finally, most of these 78 
approaches require well-trained professionals and supervision. Cost constraints may prevent 79 
implementation on a large scale or in rural areas, where therapists might not be available. 80 
Given the specific needs and requirements of MS patients, internet-based approaches could be 81 
particularly well-suited for delivering behavioral interventions to this patient population. 82 
Indeed, two small pilot RCTs in the UK and New Zealand have shown promising results for 83 
an internet-based version of a CBT-program for MS-fatigue with either added telephone or 84 
email-support16 17. We thus conducted a large RCT of a novel internet-based treatment 85 
approach and examined its effectiveness for MS-related fatigue.  86 
 87 
METHODS 88 
Study Design and Population  89 
This was a parallel group, two-arm, randomized controlled trial of a 12-week, internet-based, 90 
CBT intervention (ELEVIDA). Patients were automatically randomized to ELEVIDA or 91 
standard care control group after completing baseline outcome measures (week 0).  Follow-up 92 
of outcomes was obtained at week 12 (directly after the end of the intervention), and week 24 93 
(long term follow-up).  94 
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A decision framework for appropriate control conditions for clinical trials examining 95 
behavioural interventions has recently been published 18. According to this decision 96 
framework, participation risk for our patients was low and there is a paucity of evidence from 97 
large clinical trials in MS fatigue in general and for the efficacy of online-based therapeutic 98 
options for MS-related fatigue in particular. Thus, a standard care control group was deemed 99 
appropriate for the current stage of development for ELEVIDA 18. Participants randomized to 100 
the standard care control condition were provided with access codes to ELEVIDA after 101 
completing the week 24 assessments.  102 
The trial was approved by the ethics review committee of the Hamburg Chamber of 103 
Physicians (review number PV4772) and registered with the ISRCTN registry prior to patient 104 
enrolment (registration number ISRCTN25692173).  105 
Patients were recruited by advertisements published on the website of the German MS patient 106 
organisation (Deutsche Multiple Sklerose Gesellschaft DMSG), both by the local DMSG 107 
chapter as well as nationally. In addition, information about the study was sent out via the e-108 
newsletter of the INIMS and leaflets were distributed at the MS outpatient center, University 109 
Medical Center Hamburg-Eppendorf. 110 
Inclusion/exclusion criteria 111 
Patients were eligible if they had a diagnosis of MSa, were at least 18 years of age, reported 112 
fatigue at screening (as indicated by a score of 43 or higher on the Fatigue Scale of Motor and 113 
Cognition; FSMC; 19), reported no major neurological or psychiatric comorbidities (dementia, 114 
stroke, autism, or psychosis, although comorbid depression was allowed), and no MS relapse 115 
in the last 4 weeks.  116 
Randomization and Masking 117 
After completing the last page of the online questionnaire, patients were randomly allocated 118 
(1:1, no blocking or stratification) to ELEVIDA or to the waiting control group using a fully 119 
automated computer algorithm (concealed allocation). For the randomization, the EFS Survey 120 
platform used a random number generator built into the system to assign patients to one of the 121 
two groups (ELEVIDA or standard care control). To complete assessments 12 weeks and 24 122 
weeks after randomization, participants were invited via standardized emails at predefined 123 
times (3 reminders within 4 weeks each) by one of the study investigators (JP). All outcome 124 
measures were collected via an automated online interface.  125 
                                                 
a To verify that participants had a clinical diagnosis of MS, half of the patients were randomly selected by the EFS 
platform and were requested to send written confirmation of their diagnosis (letter signed by their neurologist or 
copies of their medical records by email, mail, or fax). Of the selected patients, 90.2% provided the requested 
confirmed diagnosis. The minimum required fatigue score and the full list of excluded neurological and psychiatric 
comorbidities were unknown to the patients when they completed screening and eligibility assessment. 
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Procedures 126 
Program development: The ELEVIDA program was jointly developed by a multidisciplinary 127 
team of physicians, psychologists, psychotherapists and IT experts. Details about the 128 
development process can be found in Supplementary Materials. The program was made 129 
available at no cost for patients in this trial. In ELEVIDA, content is based on cognitive 130 
behavioral therapy (CBT) strategies and is conveyed chiefly via the technique of a “simulated 131 
dialogue”. Program modules are comprised of an introduction and a summary and include 132 
homework tasks. Patients are advised to access the program once to twice per week. 133 
Participants are invited to respond continuously to narrative text passages provided by the 134 
program using a multiple-choice format. Depending on patients’ responses, the program 135 
tailors subsequently offered information to match the individual needs (e.g., preference for 136 
elaborated explanations, additional exercises, shorter texts, etc.).  137 
Clinical descriptors 138 
All clinical and demographic descriptors were assessed by self-report from the patients via 139 
online questionnaires. The disability ratings were derived from the Patient Determined 140 
Disease Steps (PDDS) instrument 20. It has been shown that the PDDS correlates highly with 141 
EDSS scores rated by experienced neurologists, objective tests of walking ability such as the 142 
6-minute walking test, and real world mobility as assessed by accelerometer measures 21. 143 
Outcome measures 144 
The pre-specified primary outcome measure was the Chalder Fatigue Scale. This 145 
questionnaire assesses severity of physical and mental fatigue and is not disease specific. The 146 
scale contains 11 items covering physical fatigue (items 1-7) and mental fatigue (items 8-11). 147 
Two previous cross-sectional studies in autoimmune disorders (systemic lupus erythematosus 148 
and rheumatoid arthritis) estimated the minimally important difference for improvement on 149 
the Chalder Fatigue Scale between 0·7–1·422 23 .  The Chalder Fatigue Scale has good 150 
psychometric properties 24, has been validated in MS patients 25, and is sensitive to change 25. 151 
This is particularly important as other fatigue scales frequently used in MS such as the MFIS 152 
and the FSS have not been shown to be sensitive 26. Moreover, the Chalder scale is a pure 153 
measure of fatigue severity in contrast to other frequently used fatigue scales in MS such as 154 
the MFIS, which measures impact of fatigue (rather than severity) and the FSS (which is a 155 
combination of severity and impact) as demonstrated in a recent validation study 25. The pre-156 
specified primary endpoint analysis listed in the registry entry was group differences from 157 
baseline to post treatment (i.e. 12 weeks after randomization) and 3 months later (i.e. 24 158 
weeks after randomization).  159 
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Pre-specified secondary outcome measures were MS-specific motor and cognitive fatigue 160 
measured by the Fatigue Scale for Motor and Cognitive Functions (FSMC 19), anxiety and 161 
depression measured by the Hospital Anxiety and Depression Scale (HADS-A and HADS-D, 162 
27), health-related quality of life quantified by the Hamburg Quality of Life Questionnaire for 163 
MS (HAQUAMS 28 29), and self-reported cognitive difficulties as assessed by the Multiple 164 
Sclerosis Neuropsychological Screening Questionnaire (MSNQ) 30. Activities of daily living 165 
as assessed by the Frenchay Activity Index (FAI) 31 was pre-specified as an exploratory 166 
outcome. Additional questionnaires were obtained as exploratory measures (assessing illness 167 
perception, coping, and personality traits, and responses to symptoms, see trial registration) 168 
and these will be reported separately. 169 
Statistical analyses 170 
Sample size calculation was based on the previously published face-to-face/telephone 171 
delivered CBT intervention 32 and performed using G*Power 3.1 software. Target sample size 172 
in the trial registration was 204 participants (i.e. 102 per group). Sample size was based on an 173 
estimated standardized effect size (Cohen’s d) of 0.35 (given that a fully automated program 174 
would likely have smaller effects than face-to-face therapy) with significance level α set at 175 
0.05 (one tailed) and a power of 0.80.  176 
Continuous clinical characteristics and baseline scores are summarized by means and standard 177 
deviations. Categorical clinical characteristics are described by frequencies and percentages. 178 
Treatment effects were estimated and tested using an intention-to-treat approach as primary 179 
analysis based on multiple imputations with baseline fatigue (Chalder) and sex as predictors. 180 
The number of imputations was set to 100, which is in line with recent recommendations 33. 181 
The primary analysis model was an analysis of covariance (ANCOVA) with Chalder fatigue 182 
score at week 12 as dependent variable and intervention group as factors and baseline Chalder 183 
fatigue score as covariate. The same analysis was used for secondary endpoints.  184 
We imputed missing scores at week 12 in the primary analysis and weeks 12 and 24 for 185 
follow-up analyses making a missing-at-random assumption. The sensitivity of our results to 186 
the missing at random assumption was explored by missing-not-at-random models including 187 
control-based pattern imputation and a tipping-point analysis shifting the expected values of 188 
the dropouts in the intervention group. We also re-ran the primary analysis in all patients with 189 
neurologist-confirmed diagnosis (n=120) as well as the subgroup who had accessed the 190 
program at least once (i.e. “modified” ITT) as sensitivity analyses. Additional sensitivity 191 
analyses included ANCOVA (change from baseline in the Chalder scale as dependent 192 
variable) with last observation carried forward (LOCF) adjusting for baseline Chalder scale 193 
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scores. Moreover, we computed the ANCOVA analysis using the complete cases sample (per 194 
protocol analysis) as well as a mixed effects model repeated measures (MMRM) analysis 195 
including all available follow-up data as further sensitivity analyses.  196 
Treatment group differences were estimated by least-squares means and are reported with 197 
95% confidence intervals and two-sided p-values testing the null hypothesis of no treatment 198 
difference. A p-value smaller 0.05 is considered statistically significant in the primary 199 
analysis. Secondary analyses are of an exploratory nature and were not adjusted for multiple 200 
testing. 201 
We conducted several post hoc analyses of the data to estimate clinical relevance of the 202 
achieved effects. Following FDA guidelines for patient-reported outcome measures, we 203 
analyzed data on minimal clinically important difference (MCID) in patients’ quality of life. 204 
Here, we used the Hamburg QoL Questionnaire (HAQUAMS), a validated MS-specific QoL 205 
instrument with established thresholds for clinically relevant change (threshold of 0·36 on the 206 
fatigue subscale) 28. As recommended by the FDA (UCM193282), we used the anchor-based 207 
MCID 34 and measured the treatment effect against the definitions put forth by Kieser & 208 
Hauschke 35. We also analyzed activities of daily living as a measure of ELEVIDA’s impact 209 
on patients’ every day life as measured by the Frenchay Activity Index (FAI) 31.  210 
Adverse events were not pre-specified but defined post hoc as an increase in fatigue by more 211 
than three points or an increase in levels of depression (HADS-D) from below to above the 212 
established threshold for clinically relevant symptoms (>8). Adverse events are described as 213 
frequencies and percentages by intervention group.  214 
All statistical analyses were carried out using SAS version 9.4. Patient-level data for primary 215 
and secondary outcome measures are available for download online (Supplementary File). 216 
RESULTS 217 
Participants 218 
Patients were enrolled from July 11, 2014 to November 28, 2014 (duration of the recruitment 219 
period: 140 days). The CONSORT flow chart is displayed in Figure 1, patient characteristics 220 
at baseline are provided in Table 1 and Table 2. 221 
Missing data 222 
As shown in Figure 1, the overall drop-out rate at post intervention was 19% (n=51).  223 
Treatment adherence 224 
During the study period, participants randomized to ELEVIDA accessed the program on 225 
average 14·5 times (SD 13·0) and had logged activity within the program for on average 16·3 226 
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different days (SD 17·1) during the intervention phase. A total of n=15 (11%) participants in 227 
the intervention group never accessed the program.  228 
Primary outcome 229 
Overall, fatigue levels as measured by the Chalder scale decreased in both groups but this 230 
decline was more pronounced in the ELEVIDA group (see Figure 2 and Table 3). The 231 
intention-to-treat primary analysis (multiple imputations with baseline Chalder score and sex 232 
as predictors) yielded a statistically significant treatment effect at week 12 with a mean 233 
difference on the Chalder scale of -2·74 points (95% CI -1·16; -4·32; p=0·0007; d=0·53).  234 
Numerous sensitivity analyses were conducted to confirm these results. Treatment effects 235 
were almost identical when sex was not used as a predictor in the multiple imputations model 236 
(mean difference -2·76 points (95% CI -1·17; -4·36; p=0·0007). We also ran the primary ITT 237 
analysis in the subgroup of 120 patients who had a neurologist-confirmed MS diagnosis. This 238 
analysis yielded a group difference of -2·50 points (95% CI -0·07; -4·93) and was still 239 
statistically significant (p=0·043), despite the considerably smaller sample size. When 240 
patients randomized to the treatment group who never accessed the program were excluded 241 
from the analysis (i.e. a “modified ITT analysis”), results indicated a group difference of -242 
3·33 points (95% CI -4·92; -1·74; p<0·0001). Statistically significant treatment effects at 243 
week 12 were also confirmed in sensitivity analyses using LOCF (mean difference -2·04; 244 
95% CI -0·61; -3·48; p=0·0055) and the per protocol analysis (mean difference -3·39; 95% CI 245 
-1·77; -5·01; p<0·0001). 246 
We further investigated the sensitivity of our primary analysis to the missing at random 247 
assumption. Applying a multiple imputation procedure with control-based pattern imputation 248 
resulted in a significant intervention effect of -2·53  (95% CI (-4·14; -0·3), p= 0·0020), i.e. 249 
only slightly smaller than the primary analysis. Furthermore, we carried out a tipping-point 250 
analysis investigating when the observed statistically significant treatment difference would 251 
turn into a non-significant result. This was done by gradually shifting the expected value of 252 
the dropouts in the intervention group. We found that the result would tip with an increase of 253 
3·92 points on the Chalder Fatigue Scale in drop-outs. Since it appears fairly unrealistic that 254 
the response of the dropouts would differ by such a large amount, the analysis adds further 255 
support to our primary analysis. Taken together, the primary endpoint was met in the primary 256 
as well as all sensitivity analyses. 257 
Secondary outcomes 258 
Effects on fatigue levels at week 12 were confirmed using the secondary endpoint FSMC as 259 
well as its subscales for motor fatigue and cognitive fatigue favoring ELEVIDA (see Table 3). 260 
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There were also significant reductions on anxiety as measure by the HADS-A favoring 261 
ELEVIDA. No significant effects were seen on depressive symptoms (HADS-D) or perceived 262 
cognitive problems (MSNQ). Domain-specific QoL was significantly increased for three of 263 
the HAQUAMS subscales: Fatigue, thinking, and mobility lower extremities, favoring 264 
ELEVIDA. No significant effects were detected on QoL domains mobilitiy lower extremities, 265 
mood, and communication. Levels of significance and confidence intervals for all secondary 266 
endpoints are presented in Table 3.  267 
Clinical relevance of observed treatment effects 268 
In order to address clinical relevance, we conducted additional post-hoc analyses on 269 
secondary outcomes. Anchor-based thresholds for minimally clinically important change 270 
(MCID) are the recommended way of judging clinical significance. MCID estimates are 271 
established for patients’ quality of life on the HAQUAMS scale, a pre-defined secondary 272 
endpoint of our trial. The threshold for fatigue impact on quality of life measured by the 273 
HAQUAMS is 0·36 on the fatigue subscale 28. Here, ITT analyses indicated a “probably 274 
clinically significant effect” using published interpretation guidelines 35. Finally, we analyzed 275 
the impact on patients’ daily lives using the exploratory endpoint activities of daily living 276 
(Frenchay Activity Index, FAI). Here, a significant increase was observed in the ELEVIDA 277 
group compared to the control group (FAI, mean difference -1·97; 95% CI -0·58; -3·35; 278 
p=0·0053).  279 
Long term follow-up 280 
Treatment effects remained statistically significant at 24 weeks (primary analysis multiple 281 
imputations: mean group difference on the Chalder scale of -2·19 points; 95% CI -0·57; -282 
3·82; p=0·0080). Sensitivity analyses using LOCF (-1·53 points; 95% CI -0·09; -2·96; 283 
p=0·0376) and per protocol analyses (-2·87 points; 95% CI -1·20; -4·54; p=0·0008) were also 284 
statistically significant. Finally, long-term stability was confirmed using MMRM analysis 285 
(mean difference -2·79 points; 95% CI -1·15; -4·44; p=0·0010). Group differences also 286 
remained significant at 24 weeks for the secondary endpoints FSMC and both of its subscales, 287 
and HAQUAMS subscales fatigue and thinking as well as the activities of daily living (FAI) 288 
(see Table 3). However, treatment effects were no longer significant at 24 week follow-up for 289 
anxiety (HADS-A) and the HAQUAMS subscale mobility lower extremities (see Table 3). 290 
Adverse events 291 
For this trial, there were no pre-defined safety measures / adverse events. However, we used 292 
several measures post hoc as potential adverse events. First, we examined the number of 293 
patients who showed a reliable increase in fatigue (as determined by the primary endpoint 294 
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Chalder) of 3 points or more from baseline to post intervention (week 12). Out of all patients 295 
completing week 12 this was seen in 8 patients in the ELEVIDA group and 23 patients in the 296 
control group. An increase from below to above the clinical threshold for depression (HADS-297 
D>8) was seen in 5 patients in the ELEVIDA group and 6 patients in the control group. For 298 
anxiety (HADS-A>8), this was observed in 6 patients in the ELEVIDA group and 11 patients 299 
in the control group. One patient randomized to the control group died during the trial for 300 
unknown reasons. He was 47 years of age and of moderate disability when he entered the 301 
study. We were not able to obtain more information about his death. 302 
DISCUSSION 303 
To our knowledge, this trial is the largest of any published behavioral or pharmacological 304 
fatigue treatment trial in MS to date. Beyond meeting the primary endpoint, we showed 305 
persistence of treatment benefits up to 6 months post randomization, suggesting that patients 306 
in the intervention group may have acquired new skills during the program that helped them 307 
to manage their fatigue symptoms even after they had completed the program. Moreover, we 308 
demonstrated a positive effect on activities of daily living and clinically relevant 309 
improvements in quality of life for the treatment group, which was maintained at 6 months, 310 
underscoring the robustness of our findings as well as supporting their clinical relevance. 311 
In the meta analysis by Asano & Finlayson 10, exercise interventions achieved an effect size 312 
of d=0·57 (10 trials) and education programs (including CBT) yielded d=0·54 (8 trials). 313 
Another meta-analysis including all MS exercise studies that had measures of fatigue included 314 
as primary or secondary endpoints, the standardized effect size was d=0·45 (18 trials) 12 and 315 
the most recent meta-analysis reports a standardized mean difference of 0·53 for exercise 316 
(when analyzing 26 trials with non-exercise control conditions)36. ELEVIDA in the present 317 
trial achieved an effect size of d=0·53. Thus, the effects of ELEVIDA are comparable to those 318 
achieved by highly structured and supervised exercise interventions and behavioral 319 
interventions delivered in person, although automated programs have much less requirements 320 
in terms of resources and infrastructure for delivery.  321 
Behavioral interventions (including ELEVIDA) thus have a better evidence base for treating 322 
MS fatigue than pharmacological treatments with amantadine and modafinil, where the meta 323 
analysis found non-significant effect (d=0·07; 7 trials) 10. There was also inconclusive 324 
evidence for amantadine, modafinil and pemoline in a more recent meta analysis 37. However, 325 
it should be noted that there are individual placebo-controlled trials of other drugs including 326 
aspirin 38 and vitamin D 39, which might in the future also have a sufficient evidence base for 327 
clinical use, possibly in combination with efficacious behavioral interventions for MS fatigue. 328 
 11 
Several limitations have to be considered when interpreting our results. First, the drop-out rate 329 
in the current trial was 19% and somewhat higher in the ELEVIDA group compared to the 330 
WLC group. This might indicate that the intervention is not equally suited for all patients or 331 
that additional tools to reduce attrition might be necessary. One possibility is that patients 332 
with more pronounced cognitive impairment might have had difficulties using the program 333 
and thus dropped out. However, self-reported cognitive complaints (as assessed by the 334 
MSNQ) were not related to treatment response (i.e. group x MSNQ interaction in an 335 
additional ITT analysis p=0.72). Thus, we believe (moderate) cognitive impairment is 336 
unlikely to be a major barrier for use of such programs. Attrition is a concern for any health 337 
intervention but this has to be weighted against the resources required to deliver the 338 
intervention and thus the reach and scalability of such an approach. Here, internet-based, 339 
stand-alone tools such as ELEVIDA have a clear edge over traditional delivery methods (e.g. 340 
face-to-face interventions by highly skilled therapists). Thus their public health impact can be 341 
larger even if attrition is higher than for more traditional therapies. 342 
Disease variables (including disease course, and disability ratings) were obtained using self-343 
report. However, MS diagnosis was confirmed by written reports from their neurologist in 344 
more than 90% of the selected patients and a sensitivity analysis restricted to this subsample 345 
yielded very similar estimates of the treatment effect (which were also statistically significant 346 
despite the smaller sample size of this analysis). It should also be noted that we did not assess 347 
sleep disorders in our patients, which often co-occur or overlap with fatigue in MS. In a 348 
related matter, we did not assess whether or not participants started any new or additional 349 
treatments (pharmacological or non-pharmacological) after enrolment. In future studies, it 350 
may thus be informative to explore effects of comorbid symptoms or possible co-351 
interventions on treatment outcome.   352 
Finally, our trial had no active control group. Given limited evidence for effective internet-353 
based fatigue management programs in MS on one hand and the potential impact such easily 354 
scalable approaches would have in clinical care, we feel that the care-as-usual control group 355 
chosen here was appropriate for the current stage of development of our intervention 18. 356 
Moreover, there was no indication of a nocebo response in the control group. However, the 357 
choice of control group in trials of behavioral interventions have been shown to have a 358 
pronounced effect on the observed effect size and standard care control conditions or 359 
treatment as usual typically yield the largest estimates 18 40. Thus, future trials evaluating 360 
ELEVIDA in MS should consider additional control conditions to separate specific and non-361 
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specific effects of such interventions, specifically a comparison with face-to-face CBT 362 
interventions.  363 
In conclusion, ELEVIDA and similar programs could offer an interim solution or low barrier 364 
option to help to reach patients in areas where therapists are not available or provide care to 365 
patients in settings where resources are limited.  366 
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FIGURE LEGENDS 502 
 503 
Figure 1: Study design and trial profile 504 
 505 
 506 
Figure 2: Effects of ELEVIDA on the Chalder Fatigue Scale. Mean scores (M+SEM; ITT 507 
primary analysis) are shown for the Chalder Scale before the intervention and at 12 weeks (at 508 
the end of the intervention) and 24 week follow-up. Symptoms of fatigue showed a stronger 509 
decline in the ELEVIDA group (n=139) compared to the control group (n=136) and were 510 
maintained at long-term follow-up. Group differences were statistically significant at week 12 511 
(p=0·0007) as well as week 24 (p=0·0080). 512 
 513 
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Table 1: Clinical characteristics. 515 
 516 
  ELEVIDA group Control group 
  n=139 n=136 
Age in years, mean (SD) 40.80 (11.1) 41.90 (9.4) 
Sex (female), n (%) 114 (82.0)  108 (79.0)  
Education in years, mean (SD) 14.61 (2.3) 14.91 (2.0) 
Family status, n (%)   
married/living with partner 96 (70) 100 (73) 
single/ divorced/widowed 43 (30) 36 (27) 
Employement status  (%)   
full/part time time employment 71 (51) 64 (47) 
housemaker/student/other 13 (9) 11 (8) 
unemployed/unable to work/retired 55 (40) 61 (45) 
Disease duration in years, mean (SD) 8.91 (7.5) 9.19 (7.4) 
Disease course, n (%)   
RRMS 98 (70.5) 102 (75.0) 
SPMS 21 (15.1) 19 (14.0) 
PPMS 8 (5.8) 3 (2.2) 
Unknown 12 (8.6) 12 (8.8) 
Impairment as assessed by patient 
determined disease steps (PDDS), n (%)   
not impaired 13 (9) 14 (10) 
mild impairment 51 (37) 49 (37) 
moderate impairment 27 (19) 22 (16) 
walking aid/wheel chair 38 (28) 40 (29) 
unclear 10 (7) 11 (8) 
Disease modifying therapies (DMTs), n 
(%)   
none 43 (30.9) 23 (16.9) 
Interferon 32 (23.0) 32 (23.5) 
Natalizumab 10 (7.2) 12 (8.8) 
Fumarate 19 (13.7) 17 (12.5) 
Teriflunomid 2 (1.4) 3 (2.2) 
Glatiramer acetate 10 (7.2) 19 (14.0) 
Azathioprin 1 (0.7) 1 (0.7) 
Fingolimod 12 (8.6) 13 (9.6) 
Mitoxantrone 2 (1.4) 2 (1.5) 
Immunoglobulins 0 (0.0) 2 (1.5) 
other 8 (5.8) 11 (8.1) 
Symptomatic therapies n (%)   
None 94 (67.6) 92 (67.6) 
Antidepressant 33 (23.7) 28 (20.6) 
Fatigue medication 1 (0.7) 2 (1.5) 
Other (e.g. spasticity) 11 (7.9) 14 (10.3) 
 517 
 518 
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Table 2: Baseline scores of primary, secondary and exploratory endpoints. For symptom 519 
scales (FSMC, HADS, MSNQ, HAQUAMS), higher values indicate more symptoms and 520 
higher symptom impact. For activities of daily living (FAI), higher values indicate more 521 
activity. Data are provided as mean (SD). 522 
 523 
  ELEVIDA group Control group 
  n=139 n=136 
Chalder Fatigue Scale 21.58 (5.32) 21.17 (5.02) 
FSMC total score 76.18 (12.55) 77.34 (11.12) 
FSMC cognitive 36.78 (7.89) 37.72 (6.98) 
FSMC motor 39.40 (6.33) 39.62 (5.83) 
HADS anxiety 7.83 (4.17) 7.33 (3.86) 
HADS depression 6.82 (4.02) 6.40 (3.61) 
MSNQ 25.03 (10.62) 25.28 (9.81) 
HAQUAMS fatigue 3.56 (0.88) 3.70 (0.76) 
HAQUAMS thinking 3.15 (1.02) 3.33 (0.99) 
HAQUAMS mobility upper 1.94 (0.90) 1.89 (0.88) 
HAQUAMS mobility lower 2.80 (1.18) 2.71 (1.10) 
HAQUAMS mood 2.59 (0.91) 2.46 (0.91) 
HAQUAMS communication 2.42 (0.96) 2.34 (0.88) 
FAI 31.56 (8.69) 31.81 (9.09) 
Abbreviations: FAI: Frenchay Activity Index; FSMC: Fatigue Scale for Motor and Cognition; HADS-A: Hospital Anxiety 524 
and Depression Scale – Anxiety; HADS-D: Hospital Anxiety and Depression Scale – Depression; HAQUAMS: Hamburg 525 
Quality of Life Questionnaire for Multiple Sclerosis; MSNQ: Multiple Sclerosis Neuropsychological Screening 526 
Questionnaire 527 
 528 
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Table 3: Effects of ELEVIDA on secondary and exploratory outcomes. Mean differences 530 
between the intervention groups (Intervention - Control) adjusted for baseline scores at week 531 
12 and week 24 for the secondary endpoints as assessed by intention-to-treat analysis 532 
(multiple imputations). For symptoms scales (FSMC, HADS, MSNQ, HAQUAMS), negative 533 
values favor the intervention group. For activities of daily living (FAI), positive values favor 534 
the intervention group. 535 
 Group difference at 12 wk 
Mean (95% CI) 
p value 
Group difference at 24 wk 
Mean (95% CI) 
p value 
FSMC -3.47 (-5.79; -1.15) 
p=0.0034 
-3.47 (-5.89; -1.05) 
p=0.0049 
FSMC-cognition -1.78 (-3.12; -0.44) 
p=0.0092 
-2.01 (-3.38; -0.64) 
p=0.0041 
FSMC-motor -1.71 (-0.48; -2.94) 
p=0.0064 
-1.49 (-2.74; -0.23) 
p=0.0204 
HADS-A -0.64 (-1.25; -0.03) 
p=0.0406 
-0.71 (-1.43; 0.01) 
p=0.0518 
HADS-D -0.33 (-0.96; 0.29) 
p=0.2961 
-0.50 (-1.18; 0.18)      
p=0.1507 
MSNQ -1.45 (-3.13; 0.22) 
p=0.0891 
-0.27 (-2.21; 1.66) 
p=0.7837 
HAQUAMS fatigue -0.39 (-0.57; -0.20) 
p<.0001 
-0.25 (-0.44; -0.06)      
p=0.0111 
HAQUAMS thinking -0.17 (-0.34; -0.00)     
p=0.0458 
-0.19  (-0.39; -0.00) 
p=0.0495 
HAQUAMS mobility upper -0.10 (-0.26; 0.06) 
p=0.2243      
-0.14 (-0.29; 0.01)      
p=0.0715 
HAQUAMS mobility lower -0.13 (-0.26; -0.01) 
p=0.0397 
-0.07 (-0.24; 0.09) 
p=0.3818      
HAQUAMS mood -0.11 (-0.27; 0.05) 
p=0.1848 
-0.11 (-0.30; 0.08) 
p=0.2643 
HAQUAMS communication -0.14 (-0.30; 0.03) 
p=0.1074 
-0.12 (-0.28 ; 0.05) 
p=0.1648      
FAI 1.97 (0.58; 3.35) 
p= 0.0053 
1.76 (0.20; 3.33) 
p=0.0275 
Abbreviations: FAI: Frenchay Activity Index; FSMC: Fatigue Scale for Motor and Cognition; HADS-A: Hospital Anxiety 536 
and Depression Scale – Anxiety; HADS-D: Hospital Anxiety and Depression Scale – Depression; HAQUAMS: Hamburg 537 
Quality of Life Questionnaire for Multiple Sclerosis; MSNQ: Multiple Sclerosis Neuropsychological Screening 538 
Questionnaire 539 
